Reliance on CSS to diagnose clinically significant bacterial burden in chronic wounds leads to the haphazard use of antimicrobials
Improved methods of identifying bacterial burden and infection are needed to enhance antimicrobial stewardship efforts in wound care
MolecuLight i:X can provide utility in point-of-care detection of elevated bacterial burden
Strong correlation between fluorescence and bacterial burden
MolecuLight i:X objectively detects bacterial proliferation, in contrast with pH
This study aimed to assess the efficacy and safety of a porcine peritoneum-derived matrix, a type of cellular and/or tissue product for treatment of DFUs
MolecuLight i:X imaging and measurement of bacterial protease activity (BPA) were performed weekly to evaluate bacterial load in wounds
Low bacterial loads, indicated by absence of fluorescence on MolecuLight i:X images and negative BPA, predicted wound healing
Fluorescence imaging was used to meet Joint Commission guidelines for an antimicrobial stewardship program
Combined with clinical examination of signs and symptoms of infection, the MolecuLight imaging procedure improves the clinician’s ability to diagnose infection
Antimicrobial stewardship will soon become part of standard wound center reporting
This RCT used fluorescence imaging to evaluate the effects of cold atmospheric plasma on wound area of chronic wounds
Fluorescence images were used to visualize the bacterially colonized area and compare the area before and after
50.4 % reduction of bacterial load for Group 1 and 35.0 % for Group 2 compared to the day of study
24% of VLU periwound area was colonized by high bacterial loads pre-debridement
99% reduction of bacterial signal in the wound bed after debridement using fluorescence guidance
36% of periwound bacterial signal is left behind after standard debridement in VLUs (without
the guidance of fluorescence)
MolecuLight i:X
is designated as a
MolecuLight is a proud corporate member of:
© 2022
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.